We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 45

European Commission fines pharmaceutical companies for Citalopram pay-for-delay agreements
  • McDermott Will & Emery
  • European Union
  • June 30 2013

On 19 June 2013, the European Commission announced a fine of 93.8 million for H. Lundbeck AS (Lundbeck) and a further 52.2 million of fines levied


What did you say? $31 million awarded for infringement of hearing aid patent
  • McDermott Will & Emery
  • European Union
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed


CJEU Georgetown University SPC judgment
  • McDermott Will & Emery
  • European Union
  • January 22 2014

Following hot on the heels of the 14 November 2013 opinion given by the Advocate General in Georgetown University C-48412, the Court of Justice of


High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action
  • McDermott Will & Emery
  • European Union, United Kingdom
  • January 9 2013

In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge


EU Court Confirms European Commission’s Decision on Pay-for-Delay Agreements
  • McDermott Will & Emery
  • Denmark, European Union
  • October 20 2016

On 8 September 2016, the General Court of the European Union upheld the European Commission’s decision in which the antitrust regulator imposed fines


CJEU actavis and Eli Lilly SPC judgments
  • McDermott Will & Emery
  • European Union
  • January 22 2014

In addition to giving its decision in Georgetown University C-48412, the Court of Justice of the European Union (CJEU) handed down two other


Commission publishes fourth monitoring report on pharmaceutical patent settlements
  • McDermott Will & Emery
  • European Union
  • February 11 2014

The European Commission has published its fourth Report on the Monitoring of Patent Settlements (the report), concerning pharmaceutical patent


Advocate General Jääskinen gives Georgetown University SPC opinion
  • McDermott Will & Emery
  • European Union, Netherlands, United Kingdom
  • December 16 2013

On 14 November 2013, Advocate General (AG) Jääskinen's opinion in the Dutch supplementary protection certificate (SPC) referral, Georgetown


Increased European patent protection following a landmark ruling on supplementary protection certificates
  • McDermott Will & Emery
  • European Union
  • August 30 2012

The Court of Justice of the European Union (CJEU) rendered judgment relating to a preliminary reference from the English Court of Appeal, holding that the existence of an earlier marketing authorization (MA) of a pharmaceutical product does not preclude the grant of a Supplementary Protection Certificate (SPC) for a different application of the same product


UK Supreme Court steps into line with Europe, but rejects U.S. approach
  • McDermott Will & Emery
  • European Union, United Kingdom, USA
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily